You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Bulk Pharmaceutical API Sources for NORLESTRIN FE 1/50


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for NORLESTRIN FE 1/50

Vendor Vendor Homepage Vendor Sku API Url
Starshine Chemical ⤷  Get Started Free 2023-05-5H05635 ⤷  Get Started Free
RR Scientific ⤷  Get Started Free R6430467 ⤷  Get Started Free
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for: NORLESTRIN FE 1/50

Last updated: August 1, 2025

Introduction

Norlestrin FE 1/50 is a combined oral medication comprising norethisterone and ferrous sulfate, used primarily for conditions related to hormonal imbalances and iron deficiency anemia. As an API-driven pharmaceutical product, sourcing high-quality active ingredients is critical for ensuring efficacy, safety, and regulatory compliance. This article offers a comprehensive overview of bulk API sources for norethisterone and ferrous sulfate, key considerations in procurement, and industry outlooks to assist pharmaceutical manufacturers and supply chain managers.

Understanding the API Components

Norethisterone is a synthetic progestogen, classified under 19-nortestosterone derivatives, with hormone activity that mimics progesterone. Its pharmaceutical efficacy hinges on high purity and consistent potency.

Ferrous sulfate is an iron supplement, commonly used to treat iron-deficiency anemia. Its quality is assessed based on elemental iron content, solubility, and absence of contaminants.

The combined formulation, Norlestrin FE 1/50, necessitates sourcing APIs that meet strict pharmacopeial standards (USP, EP, or JP), complemented by rigorous supplier qualification processes.


Global API Manufacturing and Supply Landscape

The global API market for hormonally active compounds and iron salts is well-established, with dominant contributions from key manufacturing regions, including India, China, Europe, and the United States. These regions have matured regulatory frameworks, manufacturing best practices, and extensive supply networks, ensuring steady API availability.

India and China collectively produce over 50% of the world's generic APIs, owing to cost competitiveness, manufacturing expertise, and regulatory expansions. European and US manufacturers underscore quality assurance, advanced process controls, and compliance with stringent regulations like the FDA's Current Good Manufacturing Practices (cGMP).


Major API Suppliers for Norethisterone

1. Indian Manufacturers

  • Hetero Labs Ltd.
    Hetero is a prominent supplier of synthetic hormones, including norethisterone, exporting globally. Their APIs comply with international standards, with facilities approved by US FDA, EMA, and other regulatory bodies.

  • G Biscuits Pharmaceutical Ltd.
    Known for a broad portfolio of hormonal APIs, G Biscuits maintains cGMP-certified plants and offers APIs that meet pharmacopeial specifications.

2. Chinese Manufacturers

  • North China Pharmaceutical Group Corporation (NCPC)
    NCPC produces norethisterone, emphasizing high purity and consistent batch quality. They hold GMP certifications recognized internationally.

  • Zhejiang Huahai Pharmaceutical Co., Ltd.
    A major API producer with a focus on steroid hormones, including norethisterone, adhering to global quality standards.

3. European and US Manufacturers

  • BASF and Sasol (via licensing agreements for steroid hormones)
    These companies supply premium-grade APIs with rigorous quality assurance and regulatory compliance.

  • Cambridge Major Laboratories
    Offers custom synthesis of hormones with validated processes.

Major API Suppliers for Ferrous Sulfate

1. Indian Suppliers

  • Serum Institute of India
    A leading manufacturer specializing in iron supplements, providing ferrous sulfate APIs conforming to pharmacopoeial standards.

  • Alpha Chemika
    Known for bulk iron salts with high purity and reliable supply chains.

2. Chinese Manufacturers

  • Shandong Yuwang Group
    Produces ferrous sulfate with ISO certification, with exports to global markets.

  • Shenzhen Capot Chemical
    Offers ferrous sulfate APIs that adhere to USP and EP specifications.

3. European and US Suppliers

  • FMC Corporation
    Supplies ferrous sulfate APIs with high purity, supported by comprehensive documentation and certifications.

  • BASF and Glentham Life Sciences
    Provide high-quality ferrous salts for pharmaceutical manufacturing.


Criteria for Selecting API Suppliers

Selecting a reliable API supplier involves multiple considerations:

  • Regulatory Compliance: Suppliers must hold cGMP certifications and be approved by relevant authorities (FDA, EMA, TGA, etc.).

  • Quality Assurance: Certificates of Analysis (CoA), purity profiles, residual solvent/impurity data, and stability testing are critical.

  • Capacity and Lead Time: Consistent supply capacity reduces risks for continuous production.

  • Cost Factors: Competitive pricing without compromising quality is essential for market competitiveness.

  • Traceability and Documentation: Robust batch records, audit trails, and transparency facilitate regulatory inspections and product liability management.

Supply Chain Risks and Mitigation Strategies

  • Raw Material Variability: Variations in raw material quality can affect API consistency. Engaging with reputable suppliers with proven QC protocols mitigates this risk.

  • Regulatory Changes: Evolving regulations may restrict certain APIs or suppliers. Regular supplier audits and geographical diversification are recommended.

  • Geopolitical and Trade Tensions: Tariffs, import restrictions, or sanctions can disrupt supply chains, underlining the importance of multi-source procurement strategies.


Emerging Trends and Industry Outlook

  • Digitalization and Traceability: Blockchain-based traceability enhances transparency and quality assurance.

  • Sustainable Manufacturing: Emphasis on greener processes and reduced environmental impact is reshaping API production.

  • Regulatory Harmonization: Efforts toward global regulatory convergence streamline supplier qualification and compliance validation.

  • Local Manufacturing Incentives: Countries incentivize local API production to mitigate international supply risks, potentially diversifying the sourcing landscape.


Conclusion

For pharmaceutical companies producing Norlestrin FE 1/50, securing a reliable supply of high-quality norethisterone and ferrous sulfate APIs is vital. Indian and Chinese manufacturers dominate the market owing to capacity and cost advantages, but European and US suppliers often lead in quality assurance. Due diligence, rigorous supplier qualification, and ongoing monitoring are essential to mitigate supply risks and assure regulatory compliance.


Key Takeaways

  • Global sourcing of APIs for Norlestrin FE 1/50 involves a strategic balance between cost, quality, and regulatory compliance.

  • Indian and Chinese manufacturers are primary sources for norethisterone and ferrous sulfate, but European and US suppliers offer premium-grade products.

  • Rigorous supplier qualification, including audits and documentation review, is critical for maintaining pharmaceutical quality standards.

  • Supply chain resilience is enhanced through geographical diversification, transparency, and adopting digital traceability tools.

  • Emerging industry trends emphasize sustainability, regulatory harmonization, and digital innovations in API sourcing.


FAQs

Q1: What are the primary quality standards for sourcing APIs for Norlestrin FE 1/50?
A: The main standards are USP, EP, and JP pharmacopoeias, which specify purity, potency, and contamination thresholds. Suppliers must also comply with cGMP regulations.

Q2: How can manufacturers ensure API supplier reliability?
A: Through comprehensive qualification processes, including audits, review of certificates of analysis, reference checks, and ongoing supplier performance monitoring.

Q3: Are there regional advantages in sourcing APIs for Norlestrin FE 1/50?
A: Yes; Indian and Chinese suppliers often offer cost-effective bulk APIs, whereas European and US suppliers provide higher assurance of quality and regulatory transparency.

Q4: What risks are associated with API sourcing from emerging markets?
A: Risks include variability in quality control, supply disruptions, and regulatory compliance challenges, mitigated by thorough qualification and diversification.

Q5: How are industry trends impacting API procurement strategies?
A: Trends such as digital traceability, sustainability, and regional manufacturing incentives are influencing sourcing decisions toward more transparent, reliable, and environmentally conscious suppliers.


Sources:
[1] Global Industry Analysts. "API Market Trends and Forecasts." 2022.
[2] U.S. Pharmacopeia (USP). "API Quality Standards." 2023.
[3] European Medicines Agency (EMA). "API Supplier Qualification." 2023.
[4] MarketWatch. "Global API Manufacturing Landscape." 2022.
[5] WHO. "Guidelines on Good Manufacturing Practices for Active Pharmaceutical Ingredients." 2021.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.